Background Despite significant advances in molecular characterization and therapeutic
targeting of advanced prostate cancer, it remains the second most common cause of cancer …

Although the prognosis of patients with localized prostate cancer is good after surgery, with
a favorable response to androgen deprivation therapy, about one third of them invariably …

A large number of novel therapeutics is currently undergoing clinical evaluation for the
treatment of prostate cancer, and small molecule signal transduction inhibitors are a …

Prostate cancer remains a major cause of cancer-related mortality. Genetic clues to the
molecular pathways driving the most aggressive forms of prostate cancer have been limited …

Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the
phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most …

Previous studies have suggested that PTEN loss is associated with p110β signaling
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …

Abstract Background The phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/AKT
pathway is frequently activated during prostate cancer (PCa) progression through loss or …

Prostate cancer is the most prevalent cancer in males, and treatment options are limited for
advanced forms of the disease. Loss of the PTEN and TP53 tumor suppressor genes is …

Purpose: Phosphatase and tensin homolog (PTEN) loss of function occurs in approximately
50% of patients with metastatic castrate-resistant prostate cancer (mCRPC), and is …

Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …